Kornimate/medical-research-clean huggingface dataset:
grape seed extract and postprandial oxidation and inflammation

Conditions: Metabolic Syndrome

Summary: the purpose of this study is to determine whether taking grape seed extract prior to eating a high fat meal will reduce the inflammatory response in people with the metabolic syndrome.

the purpose of this study is to determine whether taking grape seed extract prior to eating a high fat meal will reduce the inflammatory response in people with the metabolic syndrome. if this extract is shown to mitigate the inflammatory response induced by a high fat meal, it could potentially aid in postponing of the diagnosis of diabetes or other chronic diseases associated with high levels of inflammation.

Eligibility criteria:
inclusion criteria: the metabolic syndrome will be diagnosed on the basis of having a combination of any 3 of the following factors: 1. waist circumference of ≥ 40 inches (men) or ≥ 35 inches (women) 2. elevated triglycerides ≥150mg/dl 3. hdl cholesterol of \< 40mg/dl (men) or \< 50mg/dl (women) 4. elevated blood pressure of ≥ 130/85mmhg 5. fasting glucose of \> 100mg/dl exclusion criteria: * smokers * female subjects who are pregnant or lactating * subjects taking any medications that would interfere with outcomes of the study i.e. lipid lowering medications, anti-inflammatory drugs (i.e. ibuprofen), dietary supplements * subjects with any known allergy or intolerance to foods involved in the study (cantaloupe, egg, dairy, wheat, grape seed extract) * subjects who are actively trying to lose weight * subjects with unusual dietary habits (i.e. pica, anorexia nervosa, extreme food restriction, binging and/or purging disorders) * subjects who are addicted to drugs or alcohol or who are \<1 year recovery program * subjects who present with significant psychiatric or neurological disturbances as determined by the primary investigator (i.e. uncontrolled bipolar disorder) * subjects with documented atherosclerotic disease, inflammatory disease, diabetes mellitus, uncontrolled hypertension (≥ 140/90mmhg), liver and kidney disease as identified by routine blood tests (chemistry panels). these subjects will be referred to their primary care doctor for further care.
determining elements of anti-fungal immunity in burn patients

Conditions: Burn

Summary: scientific justification invasive fungal diseases (ifds) pose a substantial threat, especially in immunocompromised patients, necessitating urgent research focus and therapeutic advancements. the ifi-burn study, involving a cohort of patients with severe burn injury (n=276), revealed a significant ifd incidence of 31.6% and underscored their critical impact on morbidity and mortality. while fungi are present everywhere, for moulds within the environment and for yeasts within our microbiota, why certain patients develop ifds and others do not, remains poorly understood. the answer most likely resides in the impact of the burn injury on the immune response, loss of skin barrier and particular predisposing immune phenotype of patients. the immune system is composed of both cellular and humoral components, but the latter is far less studied in antifungal immunity although they exert multiple antimicrobial mechanisms.


Eligibility criteria:
inclusion criteria: burn patients * adult patients ≥ 18 years old * admission \< 4 days following burn injury * total burn surface area ≥ 15% * non opposition of the patient or his/her relatives to the research * affiliation to social security or any health insurance exclusion criteria: * pregnancy * opposition of the patient or his/her relatives * decision not to resuscitate or to limit or stop active therapies
terminal latency index, residual latency and median ulnar f latency difference in carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: terminal latency index, residual latency and median ulnar f latency difference in carpal tunnel syndrome are specific parameters for the diagnosis

carpal tunnel syndrome is the most common compression neuropathy. this study was performed to determine the value of terminal latency index, residual latency and median ulnar f latency difference to investigate their sensitivity and specificity in the diagnosis of this syndrome. we retrospectively determined the 160 patients. we evaluated the nerve conduction studies of patient and healthy arms. we recorded all nerve conduction study values.

Eligibility criteria:
inclusion criteria: * patients who had gone to electrodiagnostic study and diagnosed as carpal tunnel syndrome exclusion criteria: * any history of hereditary polyneuropathies * acquired polyneuropathies * surgery or local steroid injections for upper limbs or effect the study * any history of fracture at the sites of stimulation or recording
do we prepare patients for their digital legacy? a survey of palliative care professionals in the west midlands

Conditions: Death

Summary: conduct a questionnaire survey of palliative care professionals including doctors, nurses and social workers currently working within the west midlands to establish how much the palliative care community in the west midlands engage in preparing patients for their digital legacy and find out if there is a further education need in this community about digital legacy.


Eligibility criteria:
inclusion criteria: * palliative care professionals (medical, nursing and social worker) affiliated to a hospice in the west midlands. exclusion criteria: * medical, nursing or social worker not working in a hospice in the west midlands.
efficacy and safety of zoledronic acid in patients with bone metastases of any solid tumors or multiple myeloma

Conditions: Treatment of Bone Metastases

Summary: zoledronic acid is a medication that slows the breakdown of bone. this study will assess the efficacy and safety of zoledronic acid in chinese patients with multiple myeloma or other solid tumors with bone metastases.


Eligibility criteria:
inclusion criteria * cancer patients (multiple myeloma or other solid tumors) and confirmed evidence of bone lesions * significant bone pain exclusion criteria * poor renal function * use of other investigational drugs within 30 days of visit 2 * dental or other surgery to the jaw within 6 weeks of screening, or planned during the 4 week study other protocol-defined exclusion criteria may apply.
an extension protocol for subjects who successfully completed pro140_cd02 study

Conditions: Hiv; Human Immunodeficiency Virus

Summary: this is an extension study, to provide continued access to pro 140 to subjects who complete participation in pro140_cd02 and continue to receive clinical benefit and would require pro 140 to form a viable regimen, in the opinion of the treating physician. the patient population for this trial are treatment-experienced hiv infected patients with ccr5-tropic virus who demonstrate evidence of hiv-1 suppression after successfully completed 24 weeks of treatment in the pro140_cd02 study.


Eligibility criteria:
inclusion criteria: potential subjects are required to meet all of the following criteria for enrollment into the study. 1. subjects who have completed 24 weeks of treatment in pro 140_cd 02 study, and investigator believes subject requires continued access to pro 140 in order to continue deriving clinical benefit and maintain hiv-1 viral suppression 2. hiv-1 rna ≤ 50 copies/ml at t23 visit in pro140_cd02 study 3. both male and female patients and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception (e.g., barrier contraceptives \[male condom, female condom, or diaphragm with a spermicidal gel\], hormonal contraceptives \[implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings\], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized). females of childbearing potential must have a negative urine pregnancy test prior to receiving the first dose of study drug. 4. willing and able to participate in all aspects of the study, including use of sc medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent. exclusion criteria: potential subjects meeting any of the following criteria will be excluded from enrollment. 1. not currently enrolled in pro 140_cd 02 study 2. any active infection or malignancy requiring acute therapy (with the exception of local cutaneous kaposi's sarcoma) 3. females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study 4. any other clinical condition that, in the investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety measures
the effect of nac in decreasing the incidence of linezolid-induced thrombocytopenia in critically ill patients

Conditions: Linezolid Associated Thrombocytopenia

Summary: * study the effect of acetylcysteine on decreasing the incidence of lit in critically ill patients. * study the impact of acetylcysteine on the time to onset of lit and the time to recovery of platelets.

primary outcome: difference in incidence of lit between patients who received nac and patients who didn't. * primary outcome definition: defined as platelets \ 50% of baseline platelets. * secondary outcome: difference in time to onset of lit and time to recovery between the 2 groups. blood products transfusion, bleeding, length of stay, and in-hospital mortality incidence between 2 groups. * secondary outcome definitions: after having thrombocytopenia, regardless of discontinuation of linezolid, recovery is defined as the restoration and maintenance of platelet counts \> 70% of baseline values.

Eligibility criteria:
inclusion criteria: * all adult patients, age \> or = 18 years old, admitted to the icu with different indications. * candidates for intravenous linezolid therapy for \> or =1 day. exclusion criteria: * taking any myelosuppressive drug. * baseline platelets \< 50000. * patients with hematological malignancy. * covid-19 patients. * patients with immune thrombocytopenia. * patients who refused to sign the informed consent
a prospective randomized study comparing sentinel lymph node (sln) evaluation with standard pathological evaluation for the staging of colon carcinoma

Conditions: Colon Cancer

Summary: the objective of this trial is to define the rate of upstaging of colon carcinoma lymph node metastasis with sentinel lymph node (sln) mapping. null hypothesis: there is no difference in the rate of lymph node metastasis between conventional histopathological processing of lymph nodes and sln mapping with detailed pathologic examination using immunohistochemistry (ihc) in patients undergoing resection of colon carcinoma.


Eligibility criteria:
inclusion criteria: 1. 18 years of age 2. primary, non-metastatic \[stage i, ii (localized, node negative), or iii (localized, node positive)\] colon carcinoma confirmed by tissue biopsy or colon mass clinically consistent with cancer and eventually confirmed by pathology 3. palpable mass at time of surgery 4. capable of providing informed consent exclusion criteria: 1. prior radiation or chemotherapy 2. non-palpable colon tumor 3. recurrent or stage iv (metastatic) colon cancer 4. unable to give informed consent
sirolimus eluting stents in complex coronary lesions (scandstent)

Conditions: Ischaemic Heart Disease

Summary: the purpose of this study is to evaluate the clinical and angiographic outcome of implantation of stents eluting or not eluting sirolimus in patients with complex coronary artery lesions suitable for percutaneous coronary intervention.


Eligibility criteria:
inclusion criteria: stable, or unstable angina and/or objective signs of myocardial ischaemia lesions should be de novo and located in native vessels with a diameter \> 2.25 mm. complex lesions to be included should have at least one of the following characteristics: * ostial in location (\< 5 mm from ostium) * total occlusions with a length ≥ 15 mm * bifurcational (side branch \> 1.75 mm in diameter) * angulated (\> 45° within lesion) exclusion criteria: patients: * other severe disease with an expected survival \< 1 year * other significant cardiac disease * known allergy against paclitaxel, clopidogrel or stainless steel. * myocardial infarction within 3 days of the index procedure * linguistic difficulties needing an interpreter * renal insufficiency (p-creatinine \> 200 micromol/l) * gastrointestinal bleeding within 1 month * childbearing potential or pregnancy * participation in another study lesions: * unprotected left main disease * restenosis * lesions containing visible thrombus * treatment with other modality than balloon or stent (ablation, brachytherapy, ultrasound) in connection with the index procedure * diffuse coronary disease distal to the treated lesion * heavily calcification * lesion located in saphenous vein graft

Keywords: coronary complex lesions restenosis drug eluting stents
prophylactic use of filgrastim sd/01 in patients with hodgkin's disease receiving abvd chemotherapy

Conditions: Hodgkin Disease

Summary: prophylactic use of filgrastim sd/01 for patients with hodgkin's lymphoma receiving abvd chemotherapy.


Eligibility criteria:
inclusion: * previously untreated hodgkin's disease patients who are scheduled to receive standard abvd chemo. * histologically proven diagnosis of hodgkin's disease of any type. * bidimensionally measurable disease. * signed informed consent. * age \>/= 16 yrs. * adequate bone marrow reserve (anc\>1000/ul, platelet \>100,000/ul. * lvef\>/=50% by muga scan or echocardiogram. * serum creatinine \<2mg/dl; serum bilirubin\<2mg/dl. exclusion: * hiv positive. * pregnant women and those of child bearing age who are not using adequate contraception. * prior chemotherapy. * severe pulmonary disease including copd and asthma. * history of prior sensitivity to e.coli derived products.

Keywords: hodgkin's lymphoma dacarbazine dtic dtic-dome vinblastine velban bleomycin sulfate blenoxane blm doxorubicin hydrochloride adriamycin filgrastim g-csf neupogen pegfilgrastim granulocyte colony-stimulating factor
combination of ketogenic diet and exercise on prediabetes in female with normal weight

Conditions: PreDiabetes

Summary: individuals with prediabetes have a high risk of developing type 2 diabetes. the purpose of this study was to compare the effect of combination of ketogenic diet and aerobic exercise interventions versus ketogenic diet alone on the glucose level in prediabetes female with normal weight.

pre-diabetes is the preceding condition of diabetes, where the blood sugar level is higher than normal but lower than the diagnostic criteria of type ii diabetes and in most of the cases, this ultimately leads to the development type ii diabetes. it has been estimated that the number of pre-diabetic cases will increase to more than 470 million people worldwide, and this is understandably a worrying trend . many studies have been done on diabetes patients. however, little is known about the pre-diabetic conditions. diagnosed prediabetes was stated as any participants who did not have diabetes but who had fasting plasma glucose level of 100 - 125 mg/dl, an hba1c level of 5.7% - 6.4%, or 2-hour plasma glucose level of 140 - 199 mg/dl. treatment of pre-diabetes and prevention of the development of pre-diabetes to t2dm,through lifestyle intervention mainly includes nutritious dietary and exercises. combining a ketogenic diet with exercise is a powerful way to reducing insulin resistance, control blood glucose levels and achieve weight loss. as ketogenic diets are nowadays predictable as being useful, there is presently a shortage of research studies examining just how useful the combination of exercise and a ketogenic diet

Eligibility criteria:
inclusion criteria: 1. female with their age ranged from 40-60 years 2. body mass index (bmi) from 20-25 kg/m2 3. fasting serum glucose range 5.6 to 6.9 mmol/l 4. hemoglobin a1c value fell within the prediabetes range (5.7%-6.4%) without medications, or treatment with oral hypoglycemic agents and/or insulin. exclusion criteria: 1. renal insufficiency 2. liver disease 3. abnormal cardiovascular function 4. diabetes 5. untreated hypertension 6. dyslipidemia 7. abnormal thyroid function 8. anyone who has undergone gallbladder removal 9. musculoskeletal constraint preventing them from fully participating in the exercise intervention
chronic constipation in children among school children is assuit university children hospital

Conditions: Chronic Constipation in Children

Summary: aim of the work to show rate of constipation among school age children in assuit university children hospital

childhood constipation is a frequently overlooked global health problem, which is developing in a public health issue in many parts of the world.(1) constipation is one of the commonest digestive complaints in children(2) constipation has long been considered a symptom, rather than a disease(3) it is often perceived as infrequent motions or passage of hard stools. some defined constipation as less than 3 bowel motions per week)4( or as difficulty in passing stools (5) approximately 0.5% of school children have defecation frequency less than 3 per week and 0.3% have fecal incontinence(6) furthermore, 20% of children also have at least 1 clinical feature of constipation.7 therefore, it is important to use diagnostic criteria based on multiple symptoms to define constipation

Eligibility criteria:
inclusion criteria:school age children 4:18 years old - exclusion criteria: neonates and younger than 4years children -
assessment of visual field-related endpoints in patients with non-arteritic ischemic optic neuropathy

Conditions: Non-arteritic Ischemic Optic Neuropathy

Summary: this present research project intends to collect five quantitative test series: * perimetric examination using static stimuli, assessing the entire (80 degree) visual field with a fast thresholding algorithm (gate) \[schiefer 2008\] to know the extent/ magnitude of the visual field defect and its variability within the cohort and over time * d-bcva, using fract \[bach 2007\] and edtrs chart \[ferris 1982\] * rapd (using swinging flashlight test). * iop (using applanation tonometer) * rnft and rnfv using spectralis oct (star scan, ring scan 2,8 mm, and volume scan) optic disk morphology will be documented by fundus photography. this assessment of the above-mentioned data is needed in order to allow for estimation of the spontaneous course / fluctuation of the (quantified) functional and morphometric parameters of the n-aion patients during the follow-up period. this is essential for the estimation of the sample size of the subsequently intended sinn study, that is intended to compare different therapeutic strategies in n-aion patients.


Eligibility criteria:
inclusion criteria: - physical, intellectual and linguistic abilities, in order to understand the test requirements * willingness to comply with the protocol (4 visits) * 41 - 80 years, informed consent * acute n-aion (\< 7 d) * d-bcva \> 0.1 (2/20) * rapd ≥ 0.3 loge steps (neutral density filters) and: * spherical ametropia max. ± 8 dpt, cylindrical ametropia max. ± 3 dpt * isocoria, pupil diameter \> 3 mm exclusion criteria: * diabetic retinopathy and any other orbital, intracranial or optic nerve disease * history of epilepsy or significant psychiatric disease * medications known to affect visual field sensitivity * infections (e.g. keratitis, conjunctivitis, uveitis) * severe dry eyes * miotic drug * amblyopia * strabismus * any ocular pathology, in either eye, that may interfere with the ability to obtain visual fields, disc imaging or accurate iop readings * cataract with relevant impairment of vision * keratoconus * intraocular surgery (except for uncomplicated cataract surgery) performed \< 3 month prior to screening * history or signs of any visual pathway affection other than n-aion * history or presence of macular disease and / or macular edema * ocular trauma

Keywords: n-aion perimetry visual field loss mean defect total loss volume d-bcva rapd retinal nerve fibre thickness/volume optic nerve head
developing a novel therapy for aversive sensory experiences in autism

Conditions: Autism; Autism in Children

Summary: the goal of this study is to assess whether a new psychological treatment can lead to changes in sensory experiences in autistic young people. participants will complete a group intervention designed to help manage sensory difficulties and associated anxiety. participants will also complete tasks before and after the intervention to assess whether the treatment can lead to changes in brain and behavioural responses to sensory experiences. the main questions the study aims to answer are: 1. does the intervention improve sensory difficulties and associated anxiety in autistic young people? 2. does the intervention change brain and biological responses to sensory experiences in autistic young people? researchers will also collect feedback from participants to help improve the design and delivery of the treatment in future studies.

the purpose of this study is to pilot a group-based cognitive behavioural therapy (cbt) intervention focused on managing sensory differences associated with autism. another aim of this study is to test whether the intervention can modulate perceptual and neurophysiological markers (e.g. via electrocephalogram \[eeg\], heart rate and skin conductance) of sensory processing in autistic children and adolescents. a final aim will be to collect qualitative feedback from autistic young people with the aim of refining and improving the intervention for larger studies in the future. the main aims of the study are: 1. to assess the feasibility of a novel cbt intervention for the management of sensory difficulties and associated anxiety in autistic youth. 2. to gather proof-of-concept data that the intervention can be used to modulate sensory neurophysiological and perceptual markers. 3. to gather qualitative feedback and ppie to inform refinements on the design and delivery of the intervention for further studies.

Eligibility criteria:
inclusion criteria: * confirmed clinical diagnosis of autism * verbal/intellectual ability in average range * sufficient spoken english to be able to access the intervention * under the care of a local mental health service * not currently taking part in another psychological intervention exclusion criteria: * verbal/intellectual ability below the average range * insufficient spoken english to be able to access the intervention * currently receiving a psychological intervention * individuals at high risk of harm to themselves or others

Keywords: sensory processing anxiety cognitive behavioural therapy perception autism